Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04362826 · ClinicalTrials.gov registry record · NA
Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer
A NA study, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT04362826 is a NA study that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 100 participants.
The verdict
NCT04362826, a NA study, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of probiotics on the breast tumor microbiome and gut microbiome in breast cancer. Microorganisms that make up the microbiome (such as viruses, bacteria, and fungi) may have an important role in breast cancer development. Understanding the association of microorganisms with breast cancer may enable new ways to prevent, diagnose, and treat breast cancer. The probiotic, BIOHM, which is owned and distributed by BIOHM Health LLC, will be used in this study. BIOHM is a food supplement that is believed to balance bacteria and fungi in the body and has received the designation as Generally Recognized as Safe (GRAS) by the Food and Drug Administration (FDA). This study is being done to determine the effectiveness of BIOHM in breast cancer.
Interventions
- OTHER Placebo
- BIOLOGICAL Novel probiotic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04362826
The ClinicalTrials.gov registry entry for NCT04362826 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04362826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04362826 about?
NCT04362826 is a clinical study titled "Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer". The purpose of this study is to examine the effect of probiotics on the breast tumor microbiome and gut microbiome in breast cancer. Microorganisms that make up the microbiome (such as viruses, bacteria, and fungi) may have an important role in breast cancer development. Understanding the associatio...
What is the current status of trial NCT04362826?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-03-20. Estimated completion is 2026-12.
What interventions are being tested in trial NCT04362826?
The interventions under investigation include: Placebo (OTHER), Novel probiotic (BIOLOGICAL).
Who is sponsoring clinical trial NCT04362826?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.